ARTIMPLANT YEAR-END REPORT JANUARY - DECEMBER 2008

ARTIMPLANT YEAR-END REPORT JANUARY - DECEMBER 2008

Västra Frölunda, Sweden, February 20, 2009

• Net revenue for the fourth quarter amounted to SEK 4.6 million (5.0) and for
January-December to SEK 12.1 million (16.3)*
• The net loss for the fourth quarter totaled SEK 6.0 million (2.1) and for
January-December SEK 22.6 million (13.5)
• Earnings per share for the fourth quarter amounted to SEK -0.10 (-0.04) and
for January-December SEK -0.38 (-0.23)
• Sales of Artelon® Spacer to end-customers totaled approximately 3,500 (3,900)
units, of which 900 (1,100) were during the fourth quarter
• Sales of Artelon® Tissue Reinforcement to end-customers totaled approximately
1,000 (600) units, of which 300 (200) were during the fourth quarter
• An exclusive distributor agreement for the USA regarding Artelon® CCL for
cruciate ligament reconstruction in dogs has been signed with BioMedtrix
• Proof-of-concept animal study commenced for treatment with Artelon® of
osteoarthritis in the knee
• Over 11,000 patients have been treated with Artelon® implants up to and
including December 2008

EVENTS AFTER THE PERIOD-END 
• Spacer agreements with Small Bone Innovations have been made non-exclusive and
Artimplant's margin per unit sold has been increased significantly

N.B. This is a translation from Swedish. The Swedish version shall always take
precedence.

Artimplant will hold a telephone conference by reason of this report on February
20, 2009 at 11 am (GMT+1). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the NASDAQ OMX Nordic Exchange
Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on February 20, 2009 at 8:45 am (GMT+1).